• Sign In
  • Sign Out
  • My Account
Subscribe
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
  • Special reports
Clarivate
  • Data Snapshots
  • BioWorld
  • BioWorld MedTech
  • Infographics: Dynamic digital data analysis
  • Index insights
  • Special reports
  • Infographics: Dynamic digital data analysis
  • Trump administration impacts
  • Biopharma M&A scorecard
  • BioWorld 2024 review
  • BioWorld MedTech 2024 review
  • BioWorld Science 2024 review
  • Women's health
  • China's GLP-1 landscape
  • PFA re-energizes afib market
  • China CAR T
  • Alzheimer's disease
  • Coronavirus
  • More reports can be found here

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
    • Index insights
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
Home » Authors » Tom Wall

Tom Wall

Articles

ARTICLES

Tranzyme, Norgine Dosing in Phase III Ulimorelin Studies

Feb. 24, 2011
By Tom Wall
Postoperative ileus (POI) is generally not what comes to mind when you see the numbers "007."
Read More

After Acquisition, Genzyme's Partners Wonder What's Next

Feb. 23, 2011
By Tom Wall

Gilead Continues to Diversify with $600M Calistoga Deal

Feb. 23, 2011
By Tom Wall
Gilead Sciences Inc. made its third major acquisition in the past eight months, buying privately held Calistoga Pharmaceuticals Inc., of Seattle, for $375 million cash and $225 million in potential milestones.
Read More

After Acquisition, Genzyme's Partners Wonder What's Next

Feb. 18, 2011
By Tom Wall
Sanofi-Aventis SA's $20.1 billion acquisition of Genzyme Corp. has a number of Genzyme partners, analysts and investors wondering what happens next.
Read More

Sanofi Uses $21.2B cash, CVR to Win Grande Dame Genzyme

Feb. 17, 2011
By Tom Wall
In the end, all it took was more cash now, and a shot at more cash later, for French suitor Sanofi-Aventis SA to win over Genzyme Corp., one of the grande dames of U.S. biotechnology.
Read More

Adventrx Acquires SynthRx, Revives Sickle Cell Drug P188

Feb. 15, 2011
By Tom Wall
Adventrx Pharmaceuticals Inc. is hoping to revive a sickle cell anemia drug that all but disappeared after a disappointing Phase III trial in 1999.
Read More

Offering Adds $67.5M More for Optimer's Fidaxomicin

Feb. 14, 2011
By Tom Wall
Optimer Pharmaceuticals Inc. continued to take care of its near-term cash needs in anticipation of a commercial launch of Clostridium difficile infection (CDI) drug fidaxomicin by raising gross proceeds of $67.5 million in an underwritten public offering of 6 million shares of common stock priced at $11.25 per share, about 10.5 percent below the previous day's closing price.
Read More

Anacor-Medicis Acne Deal Worth $160M Plus

Feb. 11, 2011
By Tom Wall
Boron is a natural element found in fruits, vegetables, milk and coffee. Medicis Pharmaceutical Corp. is betting $160 million plus that in the future it will be found in a lot of people with acne.
Read More

New Geron Execs Focused on Finding Clinical Partners

Feb. 10, 2011
By Tom Wall
Almost exactly two months after closing a $100 million offering, and with $200 million cash in the bank, Geron Corp. said Wednesday that a new management team is taking over and will look for partners to share the cost of multiple Phase II trials for its telomerase inhibitor product candidate in indications including breast and lung cancers, a Phase II trial of GRN1005 in brain metastases and a pioneering Phase I trial of embryonic stem cell therapy for spinal cord injury.
Read More

Progenics Picks Salix Sales of Relistor in Potential $350M Deal

Feb. 8, 2011
By Tom Wall
If at first you don't succeed . . . Progenics Pharmaceuticals Inc. licensed rights to Relistor (methylnaltrexone bromide), its opioid-induced constipation (OIC) drug for patients with advanced disease, to Salix Pharmaceuticals Ltd. in a deal potentially worth $350 million or more.
Read More
View All Articles by Tom Wall

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for July 9, 2025.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for July 9, 2025.
  • Kidney disease illustration

    Prokidney produces positive phase II CKD data, thunderous stock surge

    BioWorld
    A mixed bag of top-line phase II data prompted stellar stock results for Prokidney Corp. and its chronic kidney disease (CKD) and diabetes therapy, rilparencel....
  • Illustration of the β2-adrenergic receptor

    Exercise-mimicking compound offers alternative to GLP-1 therapies

    BioWorld
    An experimental drug for treating diabetes and obesity has been shown to lower blood sugar levels and increase fat burning. It is a β2-adrenergic receptor (β2AR)...
  • News in brief

    BioWorld Asia
    BioWorld Asia briefs for July 8, 2025
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2025. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
    • Index insights
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe